Dextrorphan-d3 (tartrate)
(Synonyms: 右啡烷-D3酒石酸盐) 目录号 : GC47203
An Analytical Reference Material
Cas No.:1426174-16-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Dextrorphan-d3 (tartrate) is intended for use as an internal standard for the quantification of dextrorphan (tartrate) by GC- or LC-MS. Dextrorphan is categorized as an arylcyclohexylamine and is a metabolite of dextromethorphan (hydrobromide hydrate) , an antitussive found in cough medicines. Dextrorphan, while also having antitussive activity, is psychoactive, leading to the abuse of cough medicines containing the parent compound.1,2 Dextrorphan antagonizes NMDA and µ-opioid receptors (Kis = 54 and 420 nM, respectively) and inhibits norepinephrine and serotonin transporters (Kis = 340 and 401 nM, respectively).3,4,5 This product is intended for research and forensic applications.
1.Shin, E.J., Lee, P.H., Kim, H.J., et al.Neuropsychotoxicity of abused drugs: Potential of dextromethorphan and novel neuroprotective analogs of dextromethorphan with improved safety profiles in terms of abuse and neuroprotective effectsJournal of Pharmacological Sciences106(1)22-27(2008) 2.Chomchai, C., and Manaboriboon, B.Stimulant methamphetamine and dextromethorphan use among Thai adolescents: implications for health of women and childrenJ.Med.Toxicol.8(3)291-294(2012) 3.LePage, K.T., Ishmael, J.E., Low, C.M., et al.Differential binding properties of [3H]dextrorphan and [3H]MK-801 in heterologously expressed NMDA receptorsNeuropharmacology49(1)1-16(2005) 4.Kaczor, A.A., Kijkowska-Murak, U.A., and Matosiuk, S.Theoretical studies on the structure and symmetry of the transmembrane region of glutamatergic GluR5 receptorJournal of Medicinal Chemistry51(13)3765-3776(2008) 5.Codd, E.E., Shank, R.P., Schupsky, J.J., et al.Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: Structural determinants and role in antinociceptionJ. Pharmacol. Exp. Ther.274(3)1263-1270(1995)
| Cas No. | 1426174-16-4 | SDF | |
| 别名 | 右啡烷-D3酒石酸盐 | ||
| Canonical SMILES | OC1=CC=C2C[C@H](N3C([2H])([2H])[2H])[C@@]4([H])CCCC[C@@]4(CC3)C2=C1.OC([C@H](O)[C@@H](O)C(O)=O)=O | ||
| 分子式 | C17H20D3NO.C4H6O6 | 分子量 | 410.5 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4361 mL | 12.1803 mL | 24.3605 mL |
| 5 mM | 0.4872 mL | 2.4361 mL | 4.8721 mL |
| 10 mM | 0.2436 mL | 1.218 mL | 2.4361 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。